TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37656067

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI protocol (3 T/T)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Proton multiparametric MRI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sodium MRI
Number of subjects: 10
Study: 37656180

Group type: EXPERIMENTAL
Intervention: Adjunctive Brexpiprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37656252

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) + walking promotion
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (educational materials on general exercise)
Number of subjects: 31
Study: 37656263

Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Number of subjects: 174

Group type: COMPARATOR
Intervention: Historical standard of care (SCA)
Number of subjects: 174
Study: 37656286

Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: PBM
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 37656308

Group type: EXPERIMENTAL
Intervention: GC-CCP intervention (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control (n=20)
Number of subjects: 40
Study: 37656413

Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pills (CDDP) - 20 tablets before pPCI and 10 tablets 3 times daily after pPCI
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pills (CDDP)
Number of subjects: 268
Study: 37656441

Group type: EXPERIMENTAL
Intervention: Siltuximab with/without corticosteroids
Number of subjects: 102

Group type: COMPARATOR
Intervention: Corticosteroid monotherapy
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Anti-IL6-directed therapy (siltuximab or tocilizumab)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 102
Study: 37656456

Group type: EXPERIMENTAL
Intervention: Centralized EHR-based recruitment model
Number of subjects: 13523
Study: 37656493

Group type: EXPERIMENTAL
Intervention: Affective SMS text messages reminding users about feeling good after exercise (40% probability)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control reminders (30% probability)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No message (30% probability)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Affective SMS text messages requiring a response
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Affective SMS text messages in a read-only format
Number of subjects: 120
Study: 37656500

Group type: EXPERIMENTAL
Intervention: Self-reported HIV risk assessment tool with tailored feedback (group 1)
Number of subjects: 9280

Group type: EXPERIMENTAL
Intervention: Self-reported HIV risk assessment without feedback (group 2)
Number of subjects: 9280

Group type: COMPARATOR
Intervention: Government-recommended HIV education materials (control)
Number of subjects: 9280
Study: 37656683

Group type: EXPERIMENTAL
Intervention: Regular diet on postoperative day 0
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clear liquid diet on postoperative day 0
Number of subjects: 105
Study: 37656890

Group type: EXPERIMENTAL
Intervention: Implementation intentions (3,871 participants)
Number of subjects: 7835

Group type: COMPARATOR
Intervention: Control group (3,964 participants)
Number of subjects: 7835
Study: 37656930

Group type: EXPERIMENTAL
Intervention: Home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 173
Study: 37656948

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by surgery (NACT-S), n = 314
Number of subjects: 626

Group type: COMPARATOR
Intervention: Standard chemoradiotherapy (CCRT), n = 312
Number of subjects: 626
Study: 37656991

Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during periods with an AHRE burden <1 h/day
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during periods with an AHRE burden ≥20 h/day
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during IN-alert periods
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: HeartLogic algorithm during OUT-of-alert periods
Number of subjects: 568

Group type: COMPARATOR
Intervention: Matched non-AHRE group during IN-alert periods
Number of subjects: 568

Group type: COMPARATOR
Intervention: Matched non-AHRE group during OUT-of-alert periods
Number of subjects: 568

Group type: COMPARATOR
Intervention: Matched non-AHRE group
Number of subjects: 568
Study: 37657154

Group type: EXPERIMENTAL
Intervention: Semi-automated FDG PET/CT image analysis
Number of subjects: 8

Group type: COMPARATOR
Intervention: Lesion segmentation
Number of subjects: 8

Group type: COMPARATOR
Intervention: International Myeloma Working Group (IMWG) response criteria
Number of subjects: 8
Study: 37657279

Group type: EXPERIMENTAL
Intervention: Early Intervention Services (EIS) - NAVIGATE
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual Community Care (CC)
Number of subjects: 404
Study: 37657460

Group type: EXPERIMENTAL
Intervention: TTFields therapy with standard systemic therapy (investigator's choice of immune checkpoint inhibitor or docetaxel)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard systemic therapy alone
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: TTFields therapy with standard systemic therapy
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: TTFields therapy-related adverse events
Number of subjects: 276

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 276
Study: 37657461

Group type: EXPERIMENTAL
Intervention: Multimodal screening
Number of subjects: 202562

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 202562
Study: 37657462

Group type: EXPERIMENTAL
Intervention: Giredestrant plus palbociclib
Number of subjects: 221

Group type: COMPARATOR
Intervention: Anastrozole plus palbociclib
Number of subjects: 221
Study: 37657463

Group type: EXPERIMENTAL
Intervention: Adenoviral vectors expressing HSV1-TK and Flt3L, administered via injections into the tumor bed after maximal safe resection, with six escalating doses starting from 1×10 (exact dosage not specified).
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Adenoviral vectors expressing HSV1-TK and Flt3L (combined treatment).
Number of subjects: 18
Study: 37657522

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 0.125 M L-glutamic acid at 1.65 mL/kg/h for 150 min before reperfusion
Number of subjects: 451

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 0.125 M L-glutamic acid
Number of subjects: 451
Study: 37657525

Group type: EXPERIMENTAL
Intervention: TwHF+rhTNFR-Fc
Number of subjects: 504

Group type: COMPARATOR
Intervention: MTX+rhTNFR-Fc
Number of subjects: 504

Group type: COMPARATOR
Intervention: TwHF monotherapy
Number of subjects: 504

Group type: COMPARATOR
Intervention: MTX monotherapy
Number of subjects: 504
Study: 37657523

Group type: EXPERIMENTAL
Intervention: Oligofructose 8 g/d (plus 2 g/d maltodextrin)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oligofructose 8 g/d plus 2'fucosyllactose (2 g/d)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 2'fucosyllactose 2 g/d (plus 8 g/d maltodextrin)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Maltodextrin 10 g/d
Number of subjects: 92
Study: 37657559

Group type: EXPERIMENTAL
Intervention: BUP-XR (300 mg × 2, 100 mg × 4)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: BUP-XR (300 mg × 6)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: BUP-XR (for early nonresponders)
Number of subjects: 916

Group type: EXPERIMENTAL
Intervention: BUP-XR
Number of subjects: 916

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 916
Study: 37657593

Group type: EXPERIMENTAL
Intervention: Stress perfusion cardiovascular MRI (CMR) imaging
Number of subjects: 0
Study: 37657594

Group type: EXPERIMENTAL
Intervention: Pre-PCI implantation of an IMPELLA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 0
Study: 37657624

Group type: EXPERIMENTAL
Intervention: MDD patients with adulthood adversity (AA)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: MDD patients
Number of subjects: 170

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 170
Study: 37657646

Group type: EXPERIMENTAL
Intervention: Prior GDM
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Bangladesh
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Sri Lanka
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: India
Number of subjects: 1808

Group type: EXPERIMENTAL
Intervention: Higher age, lower education status, higher prior pregnancy count, prior history of GDM, family history of DM, postpartum overweight/obese status
Number of subjects: 1808
Study: 37657768

Group type: EXPERIMENTAL
Intervention: Atrasentan (endothelin receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37657939

Group type: EXPERIMENTAL
Intervention: Neflamapimod 40 mg three times daily (TID)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 37658043

Group type: EXPERIMENTAL
Intervention: Immediate access to digital imagery-competing task intervention (weeks 1-4)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed access to digital imagery-competing task intervention (weeks 5-8)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Delayed access to digital imagery-competing task intervention (after crossover)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Immediate access to digital imagery-competing task intervention
Number of subjects: 86
Study: 37658083

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biomarkers of functional adaptive immunity
Number of subjects: 20
Study: 37658205

Group type: EXPERIMENTAL
Intervention: Equecabtagene autoleucel
Number of subjects: 0
Study: 37658223

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Lebrikizumab 250 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 7105

Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 7105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7105
Study: 37658272

Group type: EXPERIMENTAL
Intervention: MammaPrint
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Combined MammaPrint and BluePrint
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: MammaPrint High Risk tumors
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: BluePrint (gLuminal B, gHER2, gBasal)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: NCT (Neoadjuvant Chemotherapy)
Number of subjects: 146
Study: 37658305

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) HIV viral load test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) HIV screening tests
Number of subjects: 0
Study: 37658323

Group type: EXPERIMENTAL
Intervention: Neighborhoods with higher disadvantage or disorder
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Neighborhood disadvantage
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Neighborhood social environment measures of chronic stress exposure
Number of subjects: 288
Study: 37658341

Group type: EXPERIMENTAL
Intervention: Motivational interviewing technique and common risk factor approach intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care information (Control)
Number of subjects: 0
Study: 37658342

Group type: EXPERIMENTAL
Intervention: Collagen plug soaked in blood
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix Grafton
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Particulate mixture of 2/3 autogenous bone chips and 1/3 deproteinized bovine bone mineral MinerOss X
Number of subjects: 24

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 24
Study: 37658365

Group type: EXPERIMENTAL
Intervention: Malnutrition
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Haemoglobin S
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Iron imbalance
Number of subjects: 688

Group type: EXPERIMENTAL
Intervention: Overall undernutrition
Number of subjects: 688
Study: 37658373

Group type: EXPERIMENTAL
Intervention: Response to Addiction Recovery (R2AR) instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: R2AR instrument
Number of subjects: 0
Study: 37658397

Group type: EXPERIMENTAL
Intervention: Home-based palliative services (Pal-Care) delivered by community health workers (CHWs)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual cancer-center-based palliative services
Number of subjects: 90
Study: 37658464

Group type: EXPERIMENTAL
Intervention: NDT-Tango (neurologic dance training through partnered Adapted Tango) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Home exercise (HEX) intervention for 8 weeks
Number of subjects: 0
Study: 37658468

Group type: EXPERIMENTAL
Intervention: Allogeneic adipose-derived mesenchymal stem cell (ASC) injection into the submandibular glands (n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo injection (CryoStor10, n=60)
Number of subjects: 120
Study: 37658603

Group type: EXPERIMENTAL
Intervention: HSV-1-targeting CRISPR formulation
Number of subjects: 3
Study: 37658755

Group type: EXPERIMENTAL
Intervention: Web-based education
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 90
Study: 37658997

Group type: EXPERIMENTAL
Intervention: Bococizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S/N ratios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bridging electrochemiluminescence (ECL) ADA assays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-bococizumab antibodies
Number of subjects: 0
Study: 37659025

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (adjuvant therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37659283

Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg per day for one week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 37659430

Group type: EXPERIMENTAL
Intervention: Persistent high risk of cardiovascular disease
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Subclinical carotid atherosclerosis
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Maintenance of cardiovascular health during midlife
Number of subjects: 370
Study: 37659435

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 37659505

Group type: EXPERIMENTAL
Intervention: Patients with CGD
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Patients with CGD-IBD
Number of subjects: 79

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 79
Study: 37659585

Group type: EXPERIMENTAL
Intervention: Transcatheter occlusion
Number of subjects: 64580

Group type: COMPARATOR
Intervention: Surgical ligation
Number of subjects: 64580

Group type: COMPARATOR
Intervention: Overall procedural closure
Number of subjects: 64580

Group type: EXPERIMENTAL
Intervention: Median age at surgical ligation
Number of subjects: 64580

Group type: EXPERIMENTAL
Intervention: Median age at transcatheter occlusion
Number of subjects: 64580
Study: 37659594

Group type: EXPERIMENTAL
Intervention: mHealth UI application (MyHealtheBladder)
Number of subjects: 286

Group type: COMPARATOR
Intervention: VA Video Connect (VVC) session delivered by trained UI providers
Number of subjects: 286
Study: 37659673

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Guselkumab 400 mg
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg (nonresponders at week 12)
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Guselkumab 400 mg (nonresponders at week 12)
Number of subjects: 313
Study: 37659841

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (rapid access to ART, naltrexone for opioid use disorder, strengths-based case management)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 225
Study: 37659907

Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 80
Study: 37660032

Group type: EXPERIMENTAL
Intervention: Timed Up and Go dual-task test (TUGdt) with verbal tasks (TUGdt-NA and TUGdt-MB)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: TUGdt-NA words/time
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: TUGdt-MB words/time
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: TUGdt parameters (time scores and TUGdt cost)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Step length during TUGdt
Number of subjects: 186
Study: 37660038

Group type: EXPERIMENTAL
Intervention: Breath gas analysis using multi-capillary column ion mobility spectrometry (MCC-IMS)
Number of subjects: 380
Study: 37660042

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Medication and Traditional Physiotherapy)
Number of subjects: 120
Study: 37660052

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dexamethasone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 300
Study: 37660376

Group type: EXPERIMENTAL
Intervention: Fibrin clot properties
Number of subjects: 0
Study: 37660438

Group type: EXPERIMENTAL
Intervention: Darolutamide
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1509
Study: 37660534

Group type: EXPERIMENTAL
Intervention: 3-transcript model (ADGRG3, ATG2A, GNLY) from POD 7
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 3-transcript model (IGHM, CD5, GNLY) from M3
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combined 3-transcript models with eGFR at POD 7
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Combined 3-transcript models with eGFR at M3
Number of subjects: 52
Study: 37660535

Group type: EXPERIMENTAL
Intervention: PD-1-based immunotherapy with tumor PD-L1 determined in lymph node metastases
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: PD-1-based immunotherapy with tumor PD-L1 determined in primary tumors
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: PD-1-based immunotherapy with tumor PD-L1 determined in skin/subcutaneous metastases
Number of subjects: 448
Study: 37660633

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) stove intervention; n = 1,590
Number of subjects: 3195

Group type: COMPARATOR
Intervention: Control group using biomass fuels; n = 1,605
Number of subjects: 3195
Study: 37660704

Group type: EXPERIMENTAL
Intervention: Weekly dupilumab (300 mg)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo/Weekly dupilumab
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Dupilumab every 2 weeks (300 mg)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo/Every 2 weeks dupilumab
Number of subjects: 227
Study: 37660711

Group type: EXPERIMENTAL
Intervention: V160 three-dose regimen (V160 at day 1, month 2, and month 6)
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: V160 two-dose regimen (V160 on day 1, placebo at month 2, and V160 at month 6)
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Placebo (saline solution at day 1, month 2, and month 6)
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: V160 three-dose regimen
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: V160 two-dose regimen
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2220
Study: 37660715

Group type: EXPERIMENTAL
Intervention: Idrevloride in hypertonic saline
Number of subjects: 123

Group type: COMPARATOR
Intervention: Hypertonic saline alone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Idrevloride alone
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 37660952

Group type: EXPERIMENTAL
Intervention: Automated Self-Administered 24-h recalls (ASA24s)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaires (FFQs)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: 4-day Food Records (4DFRs)
Number of subjects: 1082

Group type: EXPERIMENTAL
Intervention: Repeated use of 6 ASA24s, 2 FFQs, and 2 4DFRs
Number of subjects: 1082
Study: 37661005

Group type: EXPERIMENTAL
Intervention: Know Your Risk (KYR) intervention
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Conventional genetic counseling
Number of subjects: 1000
Study: 37661107

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion of glucose (22.5 g, 1 kcal/min) and oleic acid (10 g, 1 kcal/min) for 90 min
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusion with benzocaine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intraduodenal nutrient infusion
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nutrient-induced hunger and satiety sensations
Number of subjects: 25
Study: 37661237

Group type: EXPERIMENTAL
Intervention: Mattress (MAT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rigid surface (CON)
Number of subjects: 20
Study: 37661554

Group type: EXPERIMENTAL
Intervention: fSAD-dominant (FD)
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: emphysema-dominant (ED)
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: fSAD-transition (FT)
Number of subjects: 1495